Arrowhead Pharmaceuticals (ARWR) Cash from Investing Activities (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 16 years of Cash from Investing Activities data on file, last reported at -$894.3 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 112.82% year-over-year to -$894.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$704.0 million (down 25.88% YoY) and the FY2025 annual result came in at -$129.3 million, up 69.22% from the prior year.
• Cash from Investing Activities retreated to -$894.3 million in Q1 2026, from -$23.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $141.4 million in Q2 2025 to a low of -$894.3 million in Q1 2026.
• A 5-year average of -$90.3 million and a median of -$9.9 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities tumbled 830.68% — and 2025, when it soared 1934.68%.
• Tracing ARWR's Cash from Investing Activities over 5 years: stood at -$80.7 million in 2022, then jumped by 180.35% to $64.8 million in 2023, then gained by 18.62% to $76.9 million in 2024, then tumbled by 130.87% to -$23.7 million in 2025, then slumped by 3666.67% to -$894.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$894.3 million (Q1 2026), -$23.7 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.